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Abstract
Background: Electronic communication is used in various populations to achieve health goals, but evidence in
stroke is lacking. We pilot tested the feasibility and potential effectiveness of a novel personalised electronic self-
management intervention to support person-centred goal attainment and secondary prevention after stroke.
Methods: A phase I, prospective, randomised controlled pilot trial (1:1 allocation) with assessor blinding, intention-
to-treat analysis, and a process evaluation. Community-based survivors of stroke were recruited from participants in
the Australian Stroke Clinical Registry (AuSCR) who had indicated their willingness to be contacted for research
studies. Inclusion criteria include 1–2 years following hospital admission for stroke and living within 50 km of
Monash University (Melbourne). Person-centred goals were set with facilitation by a clinician using a standardised
template. The intervention group received electronic support messages aligned to their goals over 4 weeks. The
control group received only 2–3 electronic administrative messages. Primary outcomes were study retention, goal
attainment (assessed using Goal Attainment Scaling method) and satisfaction. Secondary outcomes were self-
management (Health Education Impact Questionnaire: 8 domains), quality of life, mood and acceptability.
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Results: Of 340 invitations sent from AuSCR, 73 responded, 68 were eligible and 57 (84%) completed the baseline
assessment. At the goal-setting stage, 54/68 (79%) were randomised (median 16 months after stroke): 25 to
intervention (median age 69 years; 40% female) and 29 to control (median age 68 years; 38% female). Forty-five
(83%) participants completed the outcome follow-up assessment. At follow-up, goal attainment (mean GAS-T score
≥ 50) in the intervention group was achieved for goals related to function, participation and environment (control:
environment only). Most intervention participants provided positive feedback and reported that the iVERVE
messages were easy to understand (92%) and assisted them in achieving their goals (77%). We found preliminary
evidence of non-significant improvements between the groups for most self-management domains (e.g. social
integration and support: β coefficient 0.34; 95% CI − 0.14 to 0.83) and several quality-of-life domains in favour of the
intervention group.
Conclusion: These findings support the need for further randomised effectiveness trials of the iVERVE program to
be tested in people with new stroke.
Trial registration: ANZCTR, ACTRN12618001519246. Registered on 11 September 2018—retrospectively registered.
Keywords: Stroke, eHealth, Feasibility studies, Healthcare technology
Key messages on feasibility
 What uncertainties about feasibility existed prior to
this study?
A novel, co-designed electronic self-management inter-
vention to support person-centred goal attainment and sec-
ondary prevention after stroke was developed that would
enable tailoring and the ability to personalise support mes-
sages. Prior to testing for effectiveness in a randomised con-
trolled trial (RCT), we sought to assess the feasibility of
implementing the complex (i.e. has multiple components)
intervention design, the electronic randomisation and data
collection processes, and obtain feedback from survivors of
stroke to inform the design of future RCTs.
 What are the key feasibility findings from this study?
Feasibility was determined from sufficient participants
completing the trial (> 80%), feedback that the messages
were useful and educational, requests to ‘stop’ messages
were few and there was evidence of goal attainment and
satisfaction with the program. System failures for send-
ing messages were not detected. Practical barriers in this
early test phase included the length of the intervention
being too short (4 weeks) to fully understand all the im-
plications of running the full pre-planned 12-week pro-
gram and the inclusion of participants who had their
stroke over 1 year before receiving the intervention.
 What are the implications of the feasibility findings
on the design of the main study?
The results provided information for us to refine our
study processes and procedures related to setting persona-
lised goals and assignment of messages and an indication
the intervention would be more relevant to survivors of
stroke following discharge from the hospital after a new
stroke. A mixed-method process evaluation will be per-
formed alongside the future RCTs with a phase II study to
enable testing of the new procedures in recruiting patients
directly from hospitals rather than from the community
and to assess responder burden and retention rates from a
longer intervention period.
Background
Stroke is a leading cause of global disease burden [1].
The presence of physical disability, loss of employment,
inability to participate in pre-stroke activities, social iso-
lation, anxiety [2] and depression [3] make returning to
the community difficult [4]. This can be further compli-
cated by the need to manage the risk factors that caused
the stroke to avoid further vascular events. These on-
going physical, physiological and psychosocial impacts
are associated with unplanned readmission, reduced par-
ticipation and quality of life, and unmet needs across a
range of domains [5, 6]. For people with a chronic con-
dition such as stroke, adjustments such as learning new
behaviours or modifying one’s lifestyle are necessary, but
also challenging [7]. The ease with which adjustments
occur is multifaceted and relies, in part, on a person’s
self-efficacy, including beliefs and confidence about
their capabilities in performing various everyday activ-
ities. Self-efficacy specifically influences health behav-
iours, the types of goals an individual will set and
their ability to attain them [8]. Facilitating self-
efficacy, for example by providing self-management
support, may influence how much effort individuals
invest in achieving their health goals and their resili-
ence when faced with difficulties or failure [7]. Jones
and Riazi have identified that self-efficacy is an im-
portant variable associated with outcomes such as
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quality of life, perceived health status, depression, ac-
tivities of daily living and aspects of physical function-
ing [7]. One approach to enhancing self-efficacy in
people living with stroke is through self-management
programs [7].
To maximise the effectiveness of self-management pro-
grams, effort must be made to set well-defined recovery
goals and ensure goals are person-centred (and not clin-
ician imposed) [9]. Having ongoing support to achieve
these goals is also key for goal attainment [10, 11], but
often there are barriers faced once people return to com-
munity living after discharge from the hospital. The scale
of providing such support to survivors of stroke living in
the community requires innovation in approach and deliv-
ery. Research testing novel approaches for providing sup-
port programs is required, including new or improved
technology-based products and processes. Building the
evidence base for successful solutions may provide people
with stroke who are living in the community with the ne-
cessary assistance to continue with their recovery and op-
timise their secondary prevention management [12].
The increase in the use of mobile phones and personal
computers/tablets represents an important resource for life-
style behaviour change and disease management [13, 14].
Online eHealth support tools, accessible from portable de-
vices or personal computers, are one way of optimising
self-management and support for goal attainment. This can
include support messages or reminders using electronic
communication such as short message service (SMS) or
email, as well as in-app messaging. Although SMS and
internet-based programs have been trialled in several popu-
lations [15], their use in survivors of stroke is rare and lim-
ited to medication adherence or to a subgroup of those
with hypertension or depression [14, 16, 17]. There is a
need to build the evidence base on comprehensive eHealth
messaging to enhance support for recovery, secondary pre-
vention and self-efficacy following stroke.
In 2016, we developed an innovative multicomponent
intervention comprised of standardised person-centred
goal-setting and an aligned electronic self-management
support system [18]. This intervention was specifically
designed for people with stroke who are discharged
home from the hospital. The system includes an online
database to capture participant characteristics with
automatic integration of patient characteristics, stroke
recovery and prevention goals into a purpose-built
iVERVE (inspiring Virtual Enabled Resources following
Vascular Events) messaging system. The platform has >
1200 electronic messages that were developed using
evidence-based behaviour change theory, clinical guide-
lines and independent review [18]. This new interven-
tion required testing for feasibility and acceptability in
people with stroke before application in a fully powered
effectiveness trial.
Aims
To assess the feasibility, acceptability and potential ef-
fectiveness of iVERVE as part of a pilot randomised con-
trolled trial, among a convenience sample of survivors of
stroke. Subsequently, this evidence would be used to in-
form the design of future trials.
Methods
Study design
We conducted, a prospective, two-group randomised (1:
1) controlled pilot trial using a mixed-methods PROBE
(prospective randomized, open-label, blinded-endpoint)
design with an active control (Fig. 1). The trial was con-
ducted in Melbourne, Australia.
The trial had an embedded, computer-generated ran-
domisation process (schedule developed by an independ-
ent researcher otherwise uninvolved in the trial).
Baseline and follow-up assessments were completed by
an assessor who was blind to group allocation. A partici-
pant satisfaction survey was also completed. All partici-
pant trial data were entered into the Research Electronic
Data Capture (REDCap) electronic data capture tool [19]
hosted at Monash University. REDCap is a secure, web-
based software platform designed to support data
capture for research studies and has a range of features
including interoperability with external sources [19].
The trial was retrospectively registered with Australian New
Zealand Clinical Trials Registry: ACTRN12618001519246,
registered on 11 September 2018. The Monash University
Human Research Ethics committee (CF16/1920 -
2016000979) approved the study before data collection began.
We report our methods and results in compliance with the
CONSORT 2010 Statement, including the extension for ran-
domised pilot and feasibility trials [20].
Patient and public involvement
Public involvement was obtained in two ways. First, sur-
vivors of stroke and advocates from the Stroke Founda-
tion were included on the advisory committee as part of
overseeing the development of the intervention [18].
Second, we obtained feedback from survivors of stroke
who were participants in the study during the conduct
of this pilot trial. We will also disseminate a lay sum-
mary of the study results on our project-specific website
http://recaps.com.au/ and provide this report to partici-
pants on request.
Participant recruitment and randomisation
Participants for this study were recruited from the Aus-
tralian Stroke Clinical Registry (AuSCR). The AuSCR is
a national clinical quality registry of people with acute
stroke or transient ischaemic attack. It is designed to
monitor and improve the quality of acute stroke care
[21]. Participants were included if they (1) agreed to
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participate in future research as described in their
AuSCR 90–180-day follow-up survey, (2) were aged at
least 18 years, (3) had been discharged from the hospital
within 6–12months of their last registered admission for
stroke, (4) were living in the community (but not in resi-
dential aged care facilities), (5) were located within 50
km of Monash University (Monash Health, Clayton cam-
pus), and (6) had English as their first language or did
not require an interpreter.
On behalf of the researchers, the AuSCR Office
staff mailed an invitation pack that included a con-
sent form and a pre-enrolment survey to potentially
eligible participants. The reply-paid forms were
returned to Monash University by interested partici-
pants. Subsequently, for those who completed the
consent form and who confirmed their eligibility
based on their responses to the pre-survey, an Out-
come Assessor completed their baseline (T0) inter-
views by telephone. The blinded Outcome Assessor
also completed follow-up calls after the 4-week pro-
gram was completed (T1) (Fig. 1). Once the baseline
assessment had been completed and before random-
isation, a separate telephone interview was conducted
by a clinician-researcher to help participants set 2–3
stroke recovery and prevention goals that were likely
to be attainable within the 4-week timeframe of the
intervention. The clinician-researcher was a qualified
allied health professional with expert skills in setting
recovery-focused health goals with patients after
stroke. This was done using a project-specific standar-
dised goal-setting template and procedure (see below)
[18]. To ensure standardisation in study procedures,
Fig. 1 CONSORT diagram showing flow-through study for participants assessed for eligibility
Cadilhac et al. Pilot and Feasibility Studies           (2020) 6:172 Page 4 of 13
Outcome Assessors and clinician-researchers received
relevant training by members of the investigator team.
Participants were randomly allocated 1:1 to the control
or the intervention group by an independent researcher.
Randomisation was stratified by age (< 65, 65+ years)
and modified Rankin Scale score [0–2 (no symptoms at
all or no significant disability despite symptoms), 3–5
(slight disability, moderate disability or moderately se-
vere disability)] [22].
Sample size
We sought to recruit a maximum of 50 patients per
group for this pragmatic feasibility (pilot) trial consistent
with recommendations in the literature and other stud-
ies in this field [23–27].
Control
Participants in the control group received their usual care
in the community and to avoid unblinding to group alloca-
tion received goal-setting assistance for 2–3 goals and re-
ceived 2–3 administrative messages over a 4-week period.
This included a recommendation to access the Stroke
Foundation (Australia) website for information about stroke
through bit.ly/2tjtyhE, or phoning the Strokeline.
Intervention
In addition to the goal-setting assistance received by the
control group, the intervention group also received a
comprehensive post-discharge support eHealth program
that was delivered via the iVERVE system [18]. This sys-
tem was developed by an interdisciplinary team includ-
ing communication engineers, clinicians, public health
researchers and consumers, with independent review of
messages. It enables the programming of electronic sup-
port and educational messages aligned to nominated
goals that cover the four domains of the International
Classification of Function (ICF) developed by the World
Health Organization [28]. Messages were created, based
on behaviour change theory (including social cognitive
theory, Information-Motivational-Behavioural theory
and operant condition) and behaviour change techniques
[18], under five main categories: administration and gen-
eral motivation; secondary prevention; health/body func-
tion, activities and participation (combined ICF
categories); and environment. The message bank in-
cluded over 1200 messages. Participants in the interven-
tion group received daily support messages matched to
their personal recovery and prevention goals and level of
functional ability. The messages could be tailored and
delivered via SMS or email and were personalised (by
name) and individualised, and some messages contained
hyperlinks to trusted websites. Two-way communication
was possible, e.g. ‘STOP’ messages could be received
from participants’ telecommunications. The number of
messages received did not exceed one per day and was
dependent on the number of goals set. The intervention
group also received one or two administrative or general
motivational message per week.
Outcomes
Primary outcomes for this study were defined as the
number of participants who completed the trial, the
number of goals attained and the number of participants
satisfied with the program. Goal attainment was mea-
sured using Goal Attainment Scaling (GAS) [29]. The
GAS is an established quantitative method that offers an
individualised evaluation of non-linear constructs (i.e.
patient-centred goals) based on mathematical principals
to permit generalisability for use in group comparisons
[30]. Within GAS, progress towards goal achievement is
measured with reference to the goal and scored on a 5-
point scale from − 2 (no progress has been made or per-
formance worse than baseline) to + 2 (performance
greatly exceeded expectation). A zero score indicates
achievement of the expected level of performance, as in-
dicated in the goal statement [29]. To promote reliability
and consistency, a clinical member of the research team
who was not part of the goal-setting or evaluation team
pre-populated the expected GAS levels of performance
(− 2 through + 2) [31].
Secondary outcomes were intervention dose (number
of SMS/email messages successfully sent), costs of main-
taining the iVERVE interface and sending messages, and
satisfaction with the content of eHealth messages. Other
secondary outcomes include self-management (mea-
sured with the validated Health Education Impact Ques-
tionnaire [heiQ]) [32] which covers constructs related to
enhancing self-efficacy as measured through self-
management practices such as health-directed behav-
iours, self-monitoring and insight and skill acquisition to
cope with symptoms and health problems [33]. Higher
scores characterise better skills [32]. We have previously
used this outcome in a trial of self-management pro-
grams for survivors of stroke [34]. Given the large num-
ber of people after stroke who self-report anxiety and
depression [35], we also measured emotional status
(Hospital Anxiety and Depression Scale [HADS]) with
lower scores indicating fewer symptoms [36]. Health-
related quality of life is measured by the EuroQoL-5
dimension-3 (EQ-5D-3L) level instrument and the visual
analogue scale (VAS; 0–100 with higher scores indicat-
ing better self-reported health status) [37]. We also col-
lected information on participation using the
Nottingham Extended Activities of Daily Living (NEAD
L; 0–66 with higher scores indicating independence with
everyday activities) Scale [38]. All of these health rating
scales have previously been used in stroke studies and
validated for use in stroke [38–40].
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Outcomes were measured at baseline (T0) for health
status and after the intervention (T1 after week 5).
The modified Rankin Scale [22] was used to assess the
degree of disability or dependence at baseline to assist
with the allocation of support messages based on the
level of disability.
Feasibility assessment and process evaluation
Feasibility was assessed against the variables of recruit-
ment of participants, dose of the intervention delivered,
message transmission failures, completeness of baseline
and outcome data, and respondent burden, including re-
tention. We triangulated sources of information including
administrative data, calls or email to a help-desk contact
person and log-records of electronic messaging activity.
Log-records were also used to calculate the costs of calls.
Recruitment proportion was determined by calculating
the number of consented participants as a proportion of
the eligible population and retention of consented partici-
pants. Characteristics of the non-responders were obtained
from the AuSCR. Intervention fidelity was partly assessed
by examining the number of text messages sent and those
that failed to send; measures of acceptability included the
number of respondents who sent ‘STOP’ texts and the rea-
sons for the ‘STOP’ texts (also considered a perceived
measure of burden). Feasibility of measurement and the
burden of data collection were determined by assessing the
number of clinical outcomes completed and recording the
duration of the goal-setting interviews. In our prior re-
search of a group-based self-management intervention, we
have found that survivors of stroke, despite the different
types of impairments, complete this type of health outcome
battery with acceptable response rates [41].
Satisfaction
A survey was sent to participants 1–2 weeks post-
intervention to assess their feedback with various aspects
of the intervention including goal-setting. This included
closed questions and open text fields to describe the per-
ceived benefits of the program, willingness to continue
with the program or likelihood of recommending it to
other survivors of stroke. Participants in the intervention
group were asked additional questions to elicit their per-
ceived benefits of receiving electronic health support.
These included questions about the type and frequency of
electronic messages, appropriateness of message content
and perceptions about the adequacy of the length of sup-
port. A focus group was also undertaken with a sample of
those in the intervention group [42] (data not reported).
Data analysis
Descriptive statistics were used to compare the partici-
pants’ characteristics by group allocation (intervention
or control) and also with non-responders (those who did
not reply to the invitation to participate, or were deemed
ineligible after initial screening, or were uncontactable
after initially responding, or chose not to participate
once they learnt about the project). All outcome mea-
sures were analysed using an intention-to-treat analysis.
Descriptive statistics were calculated for all variables
over the two time points (T0, T1). Due to the skewed dis-
tribution of continuous outcomes, differences between
the groups were reported as the median difference (95%
CI). Median or logistic regression models were used with
the outcome as the dependent variable (at the 4-week
follow-up) and baseline scores entered as covariates. In-
dependent variables, including group allocation, were
entered into the regression. In the sensitivity analyses
using median regression, bootstrap estimates were com-
puted for 1000 replicates for 25th, 50th and 75th quan-
tiles to calculate the change at 4 weeks relative to
baseline measurements for assessing potential within-
group differences. Where relevant, statistical significance
was set at p < 0.05 (two-sided). Open-ended responses
from the satisfaction surveys were analysed using induct-
ive thematic analysis [43]. Closed questions were sum-
marised descriptively.
For GAS, the GAS-T method was used [29]. Each goal
was given a score over 5 levels ranging from − 2 to + 2. Goals
were also weighted based on relative importance to the pa-
tient, as well as difficulty as perceived by the clinician in-
volved in the collaborative goal-setting, with each graded on
a scale of 0 (not at all difficult) to 3 (very difficult) [44]. Indi-
vidual scores were then combined to provide an overall goal
attainment score. The GAS-transformed normally distrib-
uted score (i.e. T score) was calculated for each intervention
group by goal category with a mean of 50 (SD 10) as the ref-
erence [29]. The T score was categorised by attainment of
goal status (e.g. goal not attained = T score < 50 and goal
often attained = T score ≥ 50).
All analyses were undertaken using Stata/SE 15.01
(StataCorp 2017).
Results
Feasibility outcomes: participation, retention and data
completeness
Recruitment for this study began on 28 March 2017, and
the final baseline assessments were completed on 8 Au-
gust 2017, to ensure our pilot study would be completed
in 2017. The completion of outcome assessments oc-
curred between 29 June and 14 November 2017.
During the screening and recruitment phase, 340 eli-
gible AuSCR registrants were invited to participate. Of
the 73 who returned a consent form and were subse-
quently assessed for eligibility, five were deemed unsuit-
able for this study and did not proceed to the next stage
(i.e. two participants had cognitive disabilities, two had
been admitted to hospital and one had hearing problems
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making communication for telephone outcome assess-
ments infeasible). Compared with the non-responders,
participants were more likely to be younger and born in
Australia (not statistically significant).
Among the 68 remaining candidates for inclusion in this
study, 57 (84%) completed the baseline assessment. These
participants were living at home ~ 12–24months after
their initial stroke event. However, eleven participants
(16%) did not complete the baseline assessment for the
following reasons: seven declined to participate, three did
not return a consent form and one participant did not
own a mobile phone or have an email address. At the
goal-setting interview stage, three participants were un-
contactable, leaving 54 (95%) participants who were ran-
domised (Fig. 1). Twenty-five were allocated to the
intervention group (median age 69 years; 40% female) and
29 were allocated to the control group (mean age 68 years;
38% female). Baseline characteristics were similar between
the groups (Table 1). The demographics of the partici-
pants who completed all baseline measures and set goals
were similar to individuals classified as non-responders (n
= 286; ~ 40% female; Additional file 1: Table 1). The over-
all retention in the study was 45/54 (83%) (Fig. 1).
The median minutes (interquartile range) taken to
complete assessments was 22 (15; 31) at baseline, 29 (22;
36) at follow-up and 35 (30; 45) for setting a maximum of
three goals. At T1, the outcome assessment was unable to
be collected from nine participants, with eight withdraw-
ing (4 intervention and 4 control). One intervention par-
ticipant was uncontactable. Outcome measures were able
to be collected from 45 participants across two time
points with > 95% complete data. Median time from start
to completion of follow-up was 35 days.
Goal attainment
Based on the raw GAS scaling scores, overall, 92% of
participants scored − 1 or above indicating some pro-
gress towards achieving their goals during the 4-week
period. For the whole sample, goal attainment using the
mean GAS T scores across all goals was not achieved
(mean 49, SD 13; Table 2). Among the intervention
group, goal attainment was achieved in three out of the
four goal categories: health/body function, activities, and
participation and environment, whereas goal attainment
in the control group was only achieved for goals relating
to environment tasks.
Participant views
The survey was completed by 27/54 (50%) of partici-
pants (13 intervention: 52%; 14 control: 48%). Most par-
ticipants in both groups stated they would be happy to
take part in a similar project in the future (intervention
69%, control 71%) and would recommend it to other
people with stroke (intervention 85%, control 79%).
Satisfaction with goal-setting procedures
Over 85% of participants in both groups reported that
the goal-setting form was helpful in developing their
goals. Both groups agreed that the clinicians were help-
ful in developing their goals (intervention 92%, control
72%, p = 0.16).
Perceived benefit of the electronic health support
(intervention group only)
No unintended harms or effects were reported. Most par-
ticipants believed that text or email messages helped them
achieve their goals (77%) and were a good way to receive
education about stroke (Fig. 2). Participants were comfort-
able accessing their mobile phone or computer to read
and respond to SMS or email messages and felt that the
iVERVE messages were easy to understand. This group
perceived many benefits to the electronic support mes-
sages (Fig. 3). Eleven of the 13 participants in the interven-
tion group who responded to the survey considered the
frequency of SMS/email messages received was appropri-
ate. Overall, the messages were considered easy to receive
and read (85%). However, only 54% (n = 7) reported that
they understood how to access further information from
the web links provided within the messages.
Potential benefits for self-management or health
outcomes
Among participants in the intervention group, we noted
several indicative improvements in different domains of
the heiQ at 4 weeks (Additional file 1: Table 2). For ex-
ample, in the univariable analyses in the intervention
group, the median score for constructive attitudes and
approaches was 5.8 at baseline and 6.0 at follow-up. The
median change at 4 weeks relative to baseline measure-
ments was 1.25 (95% CI 0.3, 2.2). In the sensitivity ana-
lyses, similar results in the intervention group were
found at the 50th quantile compared with 25th and 75th
quantiles for the median change at 4 weeks relative to
baseline measurements (Additional file 1: Table 3). After
adjusting for baseline measures, we found preliminary
evidence of potential improvements for most of the self-
management domains, in favour of the intervention
group compared with the control group (Table 3). For
example, for social integration and support, there a was
positive increase (coefficient 0.34) in this domain at
follow-up after adjustment for the effect of the interven-
tion on outcomes. We also noted potential improve-
ments to some quality-of-life dimensions (EQ-5D-3L):
self-care, usual activities, and pain or discomfort.
Program costs and dose
Overall, 824 electronic messages (446 SMS; 378 emails)
were sent during the intervention period (657 interven-
tion; 167 control). The average number of messages sent
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Table 1 Characteristics of participants
Baseline characteristics Control, n/N (%), N = 29d Intervention, n/N (%), N = 25d
Demographics
Age, mean (SD) 68 (10) 69 (11)
Female 11/29 (38) 10/25 (40)
Australian 20/29 (69) 20/25 (80)
Married/with partner 20/29 (69) 12/25 (48)
Live independently 7/28 (25) 9/25 (36)
Own home or unit 25/27 (93) 22/24 (92)
Retired 17/27 (63) 14/24 (58)
University educated 9/28 (32) 8/24 (33)
Preference for electronic messages
Preferred SMS communication 12/29 (41) 14/25 (56)
Use of health services and private health insurance status
Private health insurance 19/29 (66) 18/25 (72)
Hospital and extras cover 13/19 (68) 13/18 (72)
Use community services 3/29 (10) 8/25 (32)
Allied care services in last 4 weeks 5/29 (17) 5/23 (22)
Self-reported medical history
Hypercholesterolaemia 16/28 (57) 15/24 (63)
Heart attack 4/26 (15) 5/24 (21)
Atrial fibrillation 7/26 (27) 10/24 (42)
Hypertension 21/29 (72) 15/24 (63)
Sleep apnoea 3/26 (12) 4/24 (17)
Respiratory problems 3/26 (12) 3/24 (13)
Diabetes 6/28 (21) 4/24 (17)
Arthritis 11/25 (44) 11/24 (46)
Depression 4/26 (15) 6/24 (25)
Anxiety 5/26 (19) 3/24 (13)
Cancer 4/26 (15) 1/23 (4)
Other illness 3/23 (13) 6/23 (26)
Lifestyle characteristics
Smokinga
Current smoker 1/27 (4) 1/25 (4)
Past smoker 14/27 (52) 9/25 (36)
Physically activeb 9/16 (56) 15/17 (88)*
Alcohol consumption 21/28 (75) 17/25 (68)
Risky drinkingc 4/21 (19) 4/16 (25)
Healthy eating
Advised to change diet 6/29 (21) 9/25 (36)
> 5 servings of vegetables daily 1/29 (3) 2/23 (9)
> 2 servings of fruit daily 13/29 (45) 15/23 (65)
Independent 20/29 (69) 19/25 (76)
Independent: none to slight disability classified using the modified Rankin Scale 0–1 scores
SD standard deviation, SMS short message service
aSelf-report of current smoking status
bUndertaking > 20min of vigorous intensity physical activity ≥ 3 times per week
cRisky drinking is defined as ≥ 2 drinks per day for women and ≥ 4 drinks per day for men
dFor variables with missing observations, the denominator is less than the total number for each intervention group
*Statistical significance p < 0.05
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was 15 for the intervention participants and 3 for control
participants. There were no message failures and no calls
to the help desk to report problems with the messages.
In terms of returned messages, there were two ‘STOP’
requests and one request for ‘no more contact’ from the
participants (2 intervention; 1 control). The total cost
for delivering the 824 messages was 39 Australian dollars
(AUD39, or 4.7 cents per message sent).
Discussion
We provide preliminary evidence that the use of electronic
messaging to support comprehensive person-centred goal
achievement after stroke is feasible and has potential in
terms of effectiveness. In particular, we found that our
comprehensive iVERVE intervention was acceptable to
people with stroke in providing support and health infor-
mation on a broad range of recovery issues. Another aim
of this pilot study was to establish the feasibility of our
goal-setting method and acceptance of a purpose-built
iVERVE messaging system. We were encouraged that a
larger proportion of intervention participants believed that
the health professionals had been helpful in facilitating de-
velopment of person-centred goals across a range of do-
mains since they received messages tailored to these goals,
compared to the control group. Goal attainment differ-
ences between the groups in this sample of people with
chronic stroke who trialled the intervention for 4 weeks
were promising. Median T scores over 50, indicating goals
often obtained, were noted for the intervention group for
health/body function, activities and participation and en-
vironment, but not the control group. Limitations of using
the GAS include the small sample size and short interven-
tion period. It was also reassuring to find preliminary evi-
dence of improvements for most of the self-management
domains and several quality-of-life domains in favour of
the intervention group compared with the control group.
Few studies have been conducted which include
goal-setting with eHealth support. In the study by
Wan et al., people with ischaemic stroke were rando-
mised to control, or a goal-setting intervention with-
out eHealth support messages [45]. Participants in
this latter study were assisted in establishing second-
ary prevention goals during a telephone call 1 week
after discharge. Two additional follow-up calls (1 and
3 months post-discharge) were conducted by the
stroke nurse to discuss progress towards their goals.
The intervention was feasible and led to improved
medication adherence at 6 months after discharge
Table 2 Goal Attainment Scaling (GAS) at follow-up for intervention and control groups
Type of goals Overall, mean T score (SD), Ν =
42
Control, mean T score (SD), N =
23
Intervention, mean T score (SD), N =
19
All goals 49 (13) 48 (11) 49 (15)
Secondary prevention 45 (13) 45 (11) 44 (15)
Health/body function 50 (13) 48 (14) 53 (12)
Activities and
participation
53 (17) 48 (9) 53 (17)
Environment 52 (14) 50 (4) 53 (20)
SD standard deviation, GAS Goal Attainment Scaling scores: goal not attained = T score < 50, goal often attained = T score ≥ 50
Fig. 2 Acceptability of the electronic support messages—intervention group (n = 13)
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Fig. 3 Perceived benefits of electronic messages received by participants—intervention group (n = 13)
Table 3 Between-group differences: intervention minus control (adjusted analyses of the potential effect of the intervention in self-
management or health outcomes)
Outcome Effect estimate for complete case analysis
heiQ (self-management) β coefficient (95% CI)a
Positive and active engagement in life 0.07 (− 0.61, 0.74)
Health directed behaviour 0.25 (− 0.50, 1.00)
Skill and technique acquisition 0.20 (− 0.33, 0.73)
Constructive attitudes and approaches 0.00 (− 0.62, 0.62)
Self-monitoring and insight 0.29 (− 0.18, 0.75)
Health service navigation 0.26 (− 0.20, 0.72)
Social integration and support 0.34 (− 0.14, 0.83)
Emotional wellbeing − 0.08 (− 0.80, 0.63)
Emotional status β coefficient (95% CI)a
HADS: depression 0.00 (− 1.36, 1.36)
HADS: anxiety 0.33 (− 1.06, 1.73)
NEADL (participation)
Mobility − 0.89 (− 3.18, 1.41)
Kitchen 0.00 (− 0.37, 0.37)
Domestic 0.00 (− 0.96, 0.96)
Leisure 0.00 (− 2.20, 2.20)
Visual analogue scale (EQ-5D) − 1.25 (− 7.28, 4.78)
EQ-5D (quality of life) OR (95% CI)b
Mobility 1.19 (0.26, 5.40)
Self-care 0.18 (0.02, 2.56)
Usual activities 0.56 (0.12, 2.62)
Pain or discomfort 0.57 (0.12, 2.74)
Anxiety or depression 1.54 (0.19, 12.45)
CI confidence interval, heiQ Health Education Impact Questionnaire, missing individual options were replaced with the average score of the specific dimension,
HADS, Hospital Anxiety and Depression Scale, NEADL Nottingham Extended Activities of Daily Living Scale, missing individual options were replaced with the value
3 (‘On your own easily’), EQ-5D EuroQol health-related quality of life five dimensions questionnaire and Visual Analogue Scale, OR odds ratio
aMedian regression
bLogistic regression
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from the hospital [45], but there were no other differ-
ences between the groups on other health behaviour
categories or disability outcomes. The authors con-
cluded that there was a need for more effective interven-
tion strategies with increased contact, to help participants
reach guideline-recommended targets [45]. Subsequently,
these authors conducted a multicomponent intervention
study in people with hypertension and ischaemic stroke to
improve health behaviours and blood pressure control
[14]. The intervention, provided over 4 weeks, comprised
face-to-face and telephone health belief education, a par-
ticipant calendar handbook and weekly automated short
message services. With the exception of smoking and al-
cohol consumption, health behaviours targeting other risk
factors and blood pressure control improved [14], which
lends support for incorporating secondary prevention as
part of iVERVE. However, our approach is more compre-
hensive than this prior work and acknowledges the diverse
impact of stroke on many aspects of life, as well as the
need to enable support for secondary prevention.
Strengths of this study were the overall high level of ac-
ceptability for the intervention, the lack of message failures
and the demonstrated ability to recruit participants from an
established national clinical quality registry which created
recruitment efficiencies for a pilot feasibility trial. Well-
designed randomised controlled trials (RCTs) provide the
highest level of quality for assessing the efficacy of interven-
tions [46]. However, achieving recruitment targets can be
difficult, leading to extended study timeframes, additional
costs or wastage of valuable research money when studies
fail to reach targets [47]. As an alternate strategy, clinical
registries may provide vehicles to facilitate recruitment for
clinical trials, particularly trials recruiting community-
dwelling stroke survivors. We found that the use of the
AuSCR was a cost-effective way to recruit for the current
study, since between 60 and 64% of registrants at the 90–
180-day follow-up indicate their willingness to be contacted
for research [48]. Compared to those unwilling to be con-
tacted, these registrants were younger and more often male
[48]. The current study provides one of the first examples
of leveraging this registry infrastructure to conduct a clin-
ical trial in stroke. Clinical registries may also provide an ef-
ficient mechanism to monitor uptake of new evidence for
different contexts and settings and can be complementary
to conducting clinical trials [49, 50]. If our messaging inter-
vention is found to be effective in a phase III RCT, it could
be routinely monitored through national registry infrastruc-
ture such as AuSCR.
The limitations of this pilot study include the 4-week
time frame for testing the intervention and the inclusion
of participants who had their stroke over 1 year before
receiving the intervention. For pragmatic reasons, we
piloted the intervention for only 4 weeks (although the
intervention has been designed as a 12-week program)
since 4 weeks was considered sufficient to provide us with the
information required for a future phase II trial regarding pro-
gram acceptability, system integrity and feedback on when
and how it might best be used from the perspective of some-
one living with stroke. Consistency in the delivery of the inter-
vention was monitored by the number of messages that were
sent, and if any failed to send. We did not collect information
on what actions were undertaken to achieve goals. We ac-
knowledged that the findings reported in this paper may not
equate to those obtained if the full intervention had been
tested. Overall, few (17%) participants withdrew or were un-
contactable. However, we are unable to comment on whether
a greater proportion may withdraw from a larger/longer study
or one in which patients immediately discharged from the
hospital are included. A process evaluation to examine re-
sponder burden and retention rates from a longer intervention
period and the delivery of a greater number of text messages
will be considered in a future study.
There is currently little evidence to guide best practice for
supporting people with stroke in the community immediately
post-discharge [51]. In the era of widely available technology
used by most of the population at all ages, low cost, scalable
electronic support to increase self-management with profes-
sional facilitation of goal-setting may improve the transition to
home and reduce hospital readmissions. In conducting this
pilot trial, we have obtained important information to finalise
various aspects of the intervention and the design of phase II/
III trials in people with acute stroke discharged directly to
home. Specifically, the data from this initial pilot study and
our recently completed phase II study in acute stroke has in-
formed the calculation of the sample size for our phase III
study (N = 890) that has been funded by the National Health
and Medical Research Council (1162596) to trial the interven-
tion in people with stroke directly discharged from acute hos-
pitals. This Recovery-focused Community support to Avoid
readmissions and improve Participation after Stroke (ReCAPS)
trial has recently commenced (ACTRN 12618001468213).
Conclusions
With improved survival after stroke and recognised un-
met needs of those living in the community, our com-
prehensive iVERVE intervention holds promise for
addressing a range of educational and self-management
issues faced everyday by survivors of stroke. Trials to de-
termine the potential effectiveness and cost-effectiveness
in acute stroke are underway.
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